tiprankstipranks
Trending News
More News >
Blueprint Medicines Corp. (BPMC)
:BPMC
US Market
BPMC
Blueprint Medicines
RESEARCH TOOLSreports

Blueprint Medicines (BPMC) Price & Analysis

Compare
Followers

BPMC Stock Chart & Stats

$129.46
$0.00(0.00%)
--

Blueprint Medicines News

BPMC FAQ

What was Blueprint Medicines Corp.’s price range in the past 12 months?
Currently, no data Available
What is Blueprint Medicines Corp.’s market cap?
Currently, no data Available
When is Blueprint Medicines Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Blueprint Medicines Corp.’s earnings last quarter?
Currently, no data Available
Is Blueprint Medicines Corp. overvalued?
According to Wall Street analysts Blueprint Medicines Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Blueprint Medicines Corp. pay dividends?
    Blueprint Medicines Corp. does not currently pay dividends.
    What is Blueprint Medicines Corp.’s EPS estimate?
    Blueprint Medicines Corp.’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Blueprint Medicines Corp. have?
    Currently, no data Available
    What happened to Blueprint Medicines Corp.’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Blueprint Medicines Corp.?
    Currently, no hedge funds are holding shares in BPMC
    What is the TipRanks Smart Score and how is it calculated?
    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

      Company Description

      Blueprint Medicines Corp.

      Blueprint Medicines Corporation (BPMC) is a precision therapy company focused on developing targeted treatments for genomically defined cancers, rare diseases, and cancer immunotherapy. The company leverages its proprietary scientific platform to create small molecule medicines that selectively target genetic drivers of disease. Blueprint Medicines aims to improve patient outcomes through the development of transformative therapies that address the underlying causes of various diseases.

      Ownership Overview

      3.73%96.27%
      Insiders
      3.73%
      Mutual Funds
      ― Other Institutional Investors
      96.27% Public Companies and
      Individual Investors

      Options Prices

      Currently, No data available
      ---
      Popular Stocks